Searching for New Drug Interactions

1972 ◽  
Vol 6 (1) ◽  
pp. 35-37
Author(s):  
Elliot S. Vessell
Keyword(s):  
1987 ◽  
Vol 25 (20) ◽  
pp. 80-80
Author(s):  
Martin J Brodie ◽  
Ian Harrison

This book is a practical manual for the prescriber rather than a text book. The first chapter usefully explains pharmacological terms which are used later in the book. This is followed by three sections concerned with choosing drugs. The first section gives a list of ‘best buys’ for common complaints, the second looks at treatment policies and the third gives basic pharmacological information to help in making choices. Side-effects and drug interactions are presented in the next two chapters in a readily accessible form. The final chapter, called ‘Cautions,’ has some useful information not readily found elsewhere including data on teratogenesis and shelf-life of formulations. It also suggests which drugs we should stop using, and discusses factors to consider before using a new drug.


1980 ◽  
Vol 38 (4) ◽  
pp. 331-340
Author(s):  
Emilio Perucca

Interactions with antiepileptic drugs are common and may have important clinical consequences. The physician should always consider carefully the need for and the implications of adding a new drug to any therapeutic regime and should be prepared to think about the possibility of an interaction whenever an unusual response is seen. Serum drug levels can be an invaluable tool in the recognition and the management of most types of interactions, but in no case can they be a substitute for careful observations and evaluation of the patient's symptoms and physical findings.


2011 ◽  
Vol 1 (6) ◽  
pp. 135-136
Author(s):  
Misty L. Gonzalez

Ezogabine was approved by the Food and Drug Administration (FDA) in June of 2011. This article reviews clinically significant aspects of this new drug including: the FDA-approved indications, mechanism of action, administration, drug interactions, adverse effects, clinical trial evidence, innovative properties and place in therapy.


2009 ◽  
Vol 18 (2) ◽  
Author(s):  
Hege Salvesen Blix ◽  
Kirsten K. Viktil ◽  
Åsmund Reikvam

Introduction: Little is known about the occurrence of drug interactions of hospitalised patients. We aimed to identify the frequency of potential drug interactions among hospitalised patients and, furthermore, to evaluate how many of these were problematic and clinically significant. Methods: We investigated drug interactions by two methods: by applying a computerised drug-drug interaction programme and by prospective clinical evaluation. The study was carried out at departments of internal medicine and rheumatology in five Norwegian hospitals in 2002. Patient characteristics and information on drug use were recorded for 827 patients consecutively included. Medication reviews were carried out by clinical pharmacists and drug-related problems (DRPs), among which drug interactions is one category, were identified and discussed in the hospital multidisciplinary team, chaired by a physician. Retrospectively, the patients’ drug regimens were screened by using a computer programme for drug-drug interactions, DRUID. This programme is universally used in Norway and classifies DDIs into four categories according to assumed severity: A, avoid; B, avoid/take precautions; C, take precautions; D, no action needed. Results: A total of 1513 DDIs were found in 544 patients (66% of the total sample of 827 patients) by computer screening. Many of these were related to drugs started in the hospital, that is they were new drug interactions. By bedside evaluation, 99 DDIs were found in 73 patients (9%). Of these, 89 were also identified by computer screening. Thus, only 6% of the computer identified drug interactions were assessed to be clinically problematic. Interactions of all degrees of severity, according to the computer programme, were identified as problematic by bedside screening. Drugs most often causing new drug interactions were warfarin, acetylsalicylic acid, digitoxin and combinations of codeine and paracetamol. Conclusions: The majority of hospitalised patients have potential drug interactions, however, less than one in ten have interactions of clinical importance. Computer graded severity has limitations when intended to be used as an indicator for clinical importance. Another way of picking up new, possibly serious drug interactions would be to select indicator drugs, which are drugs frequently known to be involved in interactions, and then undertake the main interaction search on these drugs.


2006 ◽  
Vol 15 (6) ◽  
pp. 421-427 ◽  
Author(s):  
Naoko Yoshida ◽  
Akito Yamada ◽  
Yasuhiko Mimura ◽  
Junichi Kawakami ◽  
Isao Adachi

1996 ◽  
Vol 21 (5) ◽  
pp. 305-308
Author(s):  
Tetsuya KAMATAKI ◽  
Tsuyoshi YOKOI ◽  
Yasuko YAMAYOSHI ◽  
Katsunori NAKAMURA ◽  
Hirotaka KUSHIDA ◽  
...  

2011 ◽  
Vol 1 (6) ◽  
pp. 126-127
Author(s):  
Jamie Holmes ◽  
Robin Hieber

Clobazam was approved by the Food and Drug Administration (FDA) in October of 2011. This article reviews clinically significant aspects of this new drug including: the FDA-approved indications, mechanism of action, administration, drug interactions, adverse effects, clinical trial evidence, innovative properties and place in therapy.


Sign in / Sign up

Export Citation Format

Share Document